Weekly Chemotherapy for Small Cell Lung Cancer
Author Information
Author(s): Frasci G, Nicolella G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Natale M, Piantedosi F, Russo A, Palmeri S, Comella G, Panza N
Primary Institution: Southern Italy Cooperative Oncology Group (SICOG)-c/o National Tumor Institute of Naples
Hypothesis
The study aimed to define the antitumour activity of a weekly regimen of cisplatin, paclitaxel, and topotecan with G-CSF support in chemo-naive patients with extensive disease small cell lung cancer.
Conclusion
The weekly CPT combination with G-CSF support is a well-tolerated treatment for chemo-naive patients with extensive disease small cell lung cancer, showing promising response rates.
Supporting Evidence
- 37 patients were treated, resulting in 8 complete responses and 22 partial responses.
- The overall response rate was 81%.
- Median progression-free survival was 8 months and overall survival was 12.5 months.
- 1-year and 2-year projected survivals were 55% and 21%, respectively.
- No toxic deaths occurred during the study.
Takeaway
Doctors gave a special mix of medicines to help people with a type of lung cancer, and many of them got better without serious side effects.
Methodology
Patients received cisplatin, paclitaxel, and topotecan weekly with G-CSF support for a maximum of 12 weeks.
Limitations
The study had a small sample size and was limited to a specific patient population.
Participant Demographics
Chemo-naive patients with extensive disease small cell lung cancer.
Statistical Information
Confidence Interval
95% CI = 65–92%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website